Ciara O'Sullivan, M.B., B.Ch.

  1. Family Physician

Location

  1. Rochester, Minnesota

Languages

English
  1. Brain metastasis
  2. Breast cancer
  3. HER2 positive invasive breast cancer
  • HER2-positive breast cancer
  • Endocrine resistance
  • Breast cancer brain metastases
  • Phase I trials
  1. 2005
    MB BCh/BAOUniversity College Dublin
  2. 1998
    Diploma - Completed Leaving Certificate (580/600 points)The Institute of Education Secondary School

Certifications

  1. 2017
    General MedicineRoyal College of Physicians of Ireland

Awards and honors

  1. 2021
    Invited DiscussantSan Antonio Breast Cancer Symposium (SABCS)
  2. 2018
    Career Development AwardASCO Conquer Cancer Foundation
  3. 2017
    Invited ParticipantASCO/AACR Methods in Clinical Cancer Research
  4. 2014
    Merit AwardASCO Conquer Cancer Foundation
  5. 2014
    Highest scoring candidate of NCI fellows completing ASCO in-training exam, scored 800 points ASCO In-Training Exam (ASCO ITE)
  6. 2013
    Clinical Scholars ScholarshipSan Antonio Breast Cancer Symposium (SABCS)
  7. 2012
    Highest scoring candidate of NCI fellows completing ASCO in-training exam, scored 744/800 ASCO In-Training Exam (ASCO ITE)
  8. 2011
    Highest scoring candidate in Irish cohort of medical oncologists completing ASCO in-training exam, scored 702/800ASCO In-Training Exam (ASCO ITE)
  9. 2010
    Highest scoring candidate in Irish cohort of medical oncologists completing ASCO in-training exam; scored 566/800ASCO In-Training Exam (ASCO ITE)
  10. 2006
    Best Clinical Tutor Runner-upUniversity College Dublin
  11. 1997
    Best French StudentThe Institute of Education Secondary School
  12. 1997
    Best French StudentThe Institute of Education Secondary School

Professional memberships

  1. 2022 - present
    Steering Committee MemberAstraZeneca ENHERTU
  2. 2022 - present
    MemberMayo Clinic Institutional Review Board (IRB)
  3. 2022 - present
    Podcast HostAcademic and Community Clinical Research United (ACCRU)
  4. 2022 - present
    Steering Committee MemberHER2CLIMB-05 Clinical Trial (NCT05132582)
  5. 2021 - present
    Study ChairA011801 (CompassHER2 RD), FDA Registration Trial
  6. 2021 - present
    Principal InvestigatorTAEK-VAC-HerBy-001: TAEK-VAC-HerBy Vaccine in Advanced HER2+ Tumors
  7. 2021 - present
    MemberNCI Breast Cancer Steering Committee, neoSTEEP Working Group
  8. 2020 - 2022
    Principal InvestigatorT-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer Trial
  9. 2020 - present
    InterviewerMayo Clinic Breast Oncology Surgical Fellowship
  10. 2020 - present
    Alliance Study ChampionEA1181, (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
  11. 2020 - present
    Steering Committee MemberSGNTUC-028: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
  12. 2020 - present
    Principal InvestigatorSMX20-001: An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination with Abemaciclib for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation
  13. 2019 - present
    Principal InvestigatorTBCRC 022: A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Neratinib and Ado-Trastuzumab Emtansine (T-DM1) for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases
  14. 2019 - present
    ASCO Trainee and Early Career Council, Career Conversations, MentorAmerican Society for Clinical Oncology
  15. 2017 - present
    MemberMayo Clinic Women's Cancer Program
  16. 2017 - present
    Breast Committee MemberAlliance for Clinical Trials in Oncology
  17. 2017 - 2021
    Principal InvestigatorECTx: Minnelide 101 (MCR)- A Phase I, Multi-center, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide(TM) Capsules given alone or in combination with Protein-Bound Paclitaxel
  18. 2017 - present
    MemberMayo Clinic Comprehensive Cancer Center, Women's Cancer Program
  19. 2017 - present
    Co-Principal InvestigatorPROMISE Trial
  20. 2017 - present
    Principal InvestigatorA Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
  21. 2017 - present
    Principal InvestigatorNRG-BR004, A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
  22. 2016 - present
    MemberIrish Society of Medical Oncology
  23. 2016 - present
    MemberAmerican Association for Cancer Research
  24. 2016 - 2021
    Principal InvestigatorA Multicenter, Open-label, Phase II Study of Imprime PGG and Pembro in Subjects with Adv Melanoma Failing Treatment with CPI or TNBC Failing Front-line Chemo for Metastatic Disease / BT-CL-PGG-MEL/BCA-1621/MK3475 PN-545
  25. 2016 - present
    Principal InvestigatorA Phase II Open-label, Randomized Study of PARP Inhibition (Olaparib), Either Alone or in Combination with Anti-PDL1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)
  26. 2016 - present
    Principal InvestigatorI3Y-MC-JPBZ monarcHER: A Phase II, Randomized, Multicenter, 3-Arm, Open-label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab with or without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab
  27. 2016 - present
    Principal InvestigatorS1416, Phase II Randomized Placebo-controlled Trial of Cisplatin with or without ABT-888 (Velparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, with or without Brain Metastases
  28. 2014 - 2016
    Medical Oncology Quality Assurance Committee memberNational Institutes of Health
  29. 2014 - present
    CCR-FYI Steering CommitteeNational Institutes of Health
  30. 2013 - 2016
    MemberThe Wild Geese Network of Irish Scientists in North America
  31. 2013 - present
    ClinFelcom, NCI Clinical Fellows CommitteeNational Institutes of Health
  32. 2010 - present
    MemberEuropean Society of Medical Oncology
  33. 2010 - present
    MemberAlliance for Clinical Trials in Oncology
  34. 2010 - present
    MemberAmerican Society for Clinical Oncology
  35. 2009 - 2012
    MemberIrish Society of Medical Oncology

Publications